| Type | Subsidiary |
| HQ | Valbonne, FR |
| Founded | 2001 |
| Website | txcell.com |
| Cybersecurity rating | AMore |
TxCell was founded in 2001 and is headquartered in Valbonne, FR
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at TxCell
Stephane Boissel
CEO
Raphael Flipo
SVP, Chief Financial Officer
Francois Meyer
Chairman of the Board and Head of Research
TxCell Office Locations
TxCell has an office in Valbonne
Valbonne, FR (HQ)
Allée de la Nertière
TxCell Financials and Metrics
Summary Metrics
Founding Date | 2001 |
Total Funding | $71.6 m |
Investors | Bpifrance, Seventure Partners, Ardian, Auriga Partners, Innovation Capital, Bioam Gestion, InnoBio Fund |
TxCell Revenue
TxCell's revenue was reported to be €2.23 m in FY, 2017 which is a 24.2% decrease from the previous period.
Annual
Annual
| EUR | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|
Net Income | (8.3m) | (11.3m) | (13.6m) | (10.9m) |
Depreciation and Amortization | 460.0k | 1.1m | (326.0k) | 272.0k |
Accounts Payable | 5.8m | 213.0k | (714.0k) | (19.0k) |
Cash From Operating Activities | (6.9m) | (10.1m) | (10.4m) | (9.8m) |
Half Year
| EUR | H1, 2015 | H1, 2016 | H1, 2017 |
|---|---|---|---|
Net Income | (5.7m) | (7.1m) | (5.3m) |
Depreciation and Amortization | 257.0k | (445.0k) | 107.0k |
Accounts Payable | (146.0k) | 503.0k | 219.0k |
Cash From Operating Activities | (6.3m) | (6.1m) | (5.1m) |
| EUR | FY, 2014 |
|---|---|
Debt/Equity | 0.1 x |
Debt/Assets | 0.1 x |
Financial Leverage | 1.4 x |
TxCell Operating Metrics
Show all operating metricsTxCell Cybersecurity Score
TxCell Online and Social Media Presence
460 Twitter followers
TxCell has 460 Twitter Followers. The number of followers has increased 1.8% month over month and increased 6.9% quarter over quarter
TxCell's Trends
Twitter Engagement Stats for @TxCellSA
352
Tweets
67
Following
460
Followers
2
Tweets last 30 days
0.5
Avg. likes per Tweet
50%
Tweets with engagement
TxCell News and Updates
July 23, 2018
Sangamo Therapeutics to Acquire TxCell
RICHMOND, Calif. and VALBONNE, France, July 23, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and TxCell S.A. (ENXTPA: TXCL) announced today that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the ...
TxCell Blogs
November 07, 2018
TxCell: financial information for the 3rd quarter of 2018
TxCell today reports its financial information for the 3rd quarter of 2018.
The post TxCell: financial information for the 3rd quarter of 2018 appeared first on Txcell.com.
October 01, 2018
Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares
Stéphane Boissel, CEO of TxCell, joins Sangamo as Executive Vice President, Corporate Strategy
The post Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares appeared first on Txcell.com.
October 01, 2018
TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell
The actions provided for by the agreement entered into between TxCell and Yorkville in July 2018 have now been completed as planned.
The post TxCell terminates its OCABSA financing program following closing of the acquisition by Sangamo of a majority stake in TxCell appeared first on Txcell.com.
September 19, 2018
TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc.
2018 half-year results and update on the proposed acquisition by Sangamo Therapeutics Inc.
The post TxCell announces first-half 2018 financial results and update on the proposed acquisition by Sangamo Therapeutics, Inc. appeared first on Txcell.com.
July 23, 2018
TxCell further improves terms of its OCABSA financing program, subject to closing of its acquisition by Sangamo Therapeutics, Inc.
Agreement for Yorkville to convert the balance of its outstanding OCA at a conversion price of €1.50 per share
The post TxCell further improves terms of its OCABSA financing program, subject to closing of its acquisition by Sangamo Therapeutics, Inc. appeared first on Txcell.com.
July 23, 2018
Conference call : Proposed Acquisition of TxCell by Sangamo Therapeutics, Inc.
A conference call will be held on Monday, July 23 at 06:00pm CEST in French
The post Conference call : Proposed Acquisition of TxCell by Sangamo Therapeutics, Inc. appeared first on Txcell.com.
TxCell Frequently Asked Questions
When was TxCell founded?
TxCell was founded in 2001.
Who are TxCell key executives?
TxCell's key executives are Stephane Boissel, Raphael Flipo and Francois Meyer.
How many employees does TxCell have?
TxCell has 23 employees.
What is TxCell revenue?
Latest TxCell annual revenue is €2.2 m.
What is TxCell revenue per employee?
Latest TxCell revenue per employee is €97.1 k.
Who are TxCell competitors?
Competitors of TxCell include Bioz, Karius and eGenesis.
Where is TxCell headquarters?
TxCell headquarters is located at Allée de la Nertière, Valbonne.
Where are TxCell offices?
TxCell has an office in Valbonne.
How many offices does TxCell have?
TxCell has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies